Ahead of print
Case report
Published online: 2023-10-26

open access

Page views 226
Article views/downloads 185
Get Citation

Connect on Social Media

Connect on Social Media

Coexistence of acromegaly and pancreatic adenocarcinoma — case study

Olga Grzelak1, Violetta Rosiek2, Beata Kos-Kudła2

Abstract

Acromegaly is a rare condition characterized by increased secretion of growth hormone (GH) and insulin- like growth factor 1 (IGF-1). This disease may predispose to the development of neoplasms. This study aims to present a case of a patient with acromegaly and coexisting pancreatic adenocarcinoma and to highlight the potential positive impact of somatostatin receptor ligands used in acromegaly treatment on the potential benefits when combined with conventional pancreatic adenocarcinoma therapy.

Article available in PDF format

View PDF Download PDF file

References

  1. Durmuş ET, Atmaca A, Çolak R, et al. Cancer prevalence and cancer screening in patients with acromegaly: a single center experience. Endocrine. 2022; 77(2): 363–371.
  2. Gierach M, Junik R. Aberrations in carbohydrate metabolism in patients with diagnosed acromegaly - observational study. Endokrynol Pol. 2022; 73(4): 743–744.
  3. Esposito D, Ragnarsson O, Johannsson G, et al. Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study. J Clin Endocrinol Metab. 2021; 106(12): 3487–3496.
  4. Wolinski K, Stangierski A, Dyrda K, et al. Risk of malignant neoplasms in acromegaly: a case-control study. J Endocrinol Invest. 2017; 40(3): 319–322.
  5. Boguszewski CL, Boguszewski MC, Kopchick JJ. Growth hormone, insulin-like growth factor system and carcinogenesis. Endokrynol Pol. 2016; 67(4): 414–426.
  6. Ruchala M, Wolinski K. Health-Related complications of acromegaly-risk of malignant neoplasms. Front Endocrinol (Lausanne). 2019; 10: 268.
  7. Suleiman Y, Mahipal A, Shibata D, et al. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015; 76(3): 481–487.
  8. Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc. 2022; 97(2): 333–346.
  9. Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020; 21(5): 1682.
  10. Guo X, Wang K, Yu S, et al. Patient characteristics, diagnostic delays, treatment patterns, treatment outcomes, comorbidities, and treatment costs of acromegaly in china: a nationwide study. Front Endocrinol (Lausanne). 2020; 11: 610519.
  11. Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020; 21(4): 667–678.
  12. Quinkler M, Petroff D, Knappe UJ, et al. participants of the German Acromegaly Registry. Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. Eur J Endocrinol. 2020; 182(3): 275–284.
  13. Campana C, Corica G, Nista F, et al. Emerging drugs for the treatment of acromegaly. Expert Opin Emerg Drugs. 2020; 25(4): 409–417.
  14. Puig-Domingo M, Bernabéu I, Picó A, et al. Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). 2021; 12: 648411.
  15. Dal J, Leisner MZ, Hermansen K, et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab. 2018; 103(6): 2182–2188.
  16. Ságová I, Mokáň M, Payer J, et al. Pegvisomant in the treatment of acromegaly. Vnitr Lek. 2022; 68(E-7): 17–22.
  17. Ritvonen E, Löyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer. 2016; 23(6): 469–480.
  18. Petroff D, Tönjes A, Grussendorf M, et al. The incidence of cancer among acromegaly patients: results from the german acromegaly registry. J Clin Endocrinol Metab. 2015; 100(10): 3894–3902.
  19. Durmaz S, Gungunes A, Oguz D, et al. A rare case of acromegaly concomitant with pancreatic adenocarcinoma. Endocrine Abstracts. 2016.
  20. Mutgan AC, Besikcioglu HE, Wang S, et al. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Mol Cancer. 2018; 17(1): 66.
  21. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861.
  22. Li Y, Tang CG, Zhao Yu, et al. Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8 edition American Joint Committee on Cancer criteria. World J Gastroenterol. 2017; 23(15): 2757–2762.
  23. Vitale G, Dicitore A, Sciammarella C, et al. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocr Relat Cancer. 2018; 25(6): R351–R364.
  24. Dummer R, Michielin O, Nägeli MC, et al. Phase I, open-label study of pasireotide in patients with wild type and -wild type, unresectable and/or metastatic melanoma. ESMO Open. 2018; 3(5): e000388.
  25. Samain R, Brunel A, Douché T, et al. Pharmacologic normalization of pancreatic cancer-associated fibroblast secretome impairs prometastatic cross-talk with macrophages. Cell Mol Gastroenterol Hepatol. 2021; 11(5): 1405–1436.